-Accelerating commercialization of wireless power supplies for EVs and active pharmaceutical ingredients with an eye on the Indian and African markets- TOKYO–(BUSINESS WIRE)–#IITH–Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) will establish a new research and development base in Telangana, India, in April 2026, to advance and reinforce its global R&D strategy. The base will be … [Read more…]
DUBLIN–(BUSINESS WIRE)–$PRTA #Prothena–Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced partner presentations on clinical updates from prasinezumab for the treatment of Parkinson’s disease and BMS-986446 for the treatment of Alzheimer’s disease at the International Conference on Alzheimer’s and Parkinson’s Diseases … [Read more…]
The free fitness platform marks milestone with multi-week challenge, new features, and livestream giveaway. INDUSTRY, Calif.–(BUSINESS WIRE)–SunnyFit, the free fitness app developed by Sunny Health & Fitness, is celebrating its fourth anniversary with the Year 4 Everyone Challenge & Giveaways Event, running from March 6 through March 26, 2026. The celebration highlights the platform’s growing … [Read more…]
SEATTLE–(BUSINESS WIRE)–Omeros Corporation (NASDAQ: OMER) today announced that it will host an industry session at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on March 22, 2026, from 2:30pm – 4pm CET in Madrid, Spain. The session, titled “Advances in TA-TMA Treatment: Evaluating the Role of a Novel Targeted … [Read more…]
SEATTLE & COLUMBUS, Ohio–(BUSINESS WIRE)–#BioTech–Curi Bio, a world leader in human-relevant 3D tissue technology, and Battelle, the world’s largest independent nonprofit research and development organization, today announced a strategic partnership to commercialize next-generation Neuromuscular Junction (NMJ) assay technology. This collaboration combines Curi Bio’s innovative microphysiological systems with Battelle’s extensive GLP-ready infrastructure to offer a transformative, … [Read more…]
In the U.S., FDA approval establishes Opdivo in combination with doxorubicin, vinblastine and dacarbazine (AVD) as the first immunotherapy combination approved for adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin Lymphoma (cHL) With approval in the EU, Opdivo in combination with brentuximab vedotin is now the … [Read more…]
Macau SAR, China regulator grants approval for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in patients with BCG-unresponsive NMIBC with CIS ± papillary tumors Authorization follows a reliance-based review referencing prior FDA and EMA decisions First ANKTIVA authorization in Asia, supporting ongoing global expansion across 34 countries and territories CULVER CITY, Calif.–(BUSINESS WIRE)–ImmunityBio, Inc. (NASDAQ: IBRX), today announced … [Read more…]
– New, late-breaking 54-week data for povorcitinib in hidradenitis suppurativa (STOP-HS1 & STOP-HS2) to be highlighted – Featured abstracts for ruxolitinib cream (Opzelura®) and povorcitinib include multiple ePosters in atopic dermatitis, hidradenitis suppurativa and vitiligo WILMINGTON, Del.–(BUSINESS WIRE)–$INCY #AAD2026–Incyte (Nasdaq:INCY) today announced that data from key programs in its Inflammation and Autoimmunity (IAI) franchise will … [Read more…]
VENLO, the Netherlands–(BUSINESS WIRE)–$QGEN #QIAGEN–QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN’s website here. QIAGEN will … [Read more…]
The first group of patients in the GS010 AAC program were treated at the 15-20 National Hospital in Paris on March 19. The REVISE dose-ranging study is proceeding according to the planned timeline. PARIS–(BUSINESS WIRE)–Regulatory News: The 15-20 National Hospital (l’Hôpital national des 15-20) in Paris and GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), … [Read more…]
